Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARTACUS
2023-510085-27-00Phase 3Authorised
- Sponsor
- Ghent University Hospital
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of golimumab and methotrexate in peripheral spondyloarthritis (pSpA) (3 arms), sponsored by Ghent University Hospital. Primary endpoint: Clinical remission rate. Planned start Sep 2024; status: authorised.
02
Drugs
golimumabmethotrexate
03
Conditions
peripheral spondyloarthritis (pSpA)
Beyond the preview
Go deeper on 2023-510085-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510085-27-00.